United States Patent 6,715,485: Scope and Claims Analysis for Nasal Delivery Devices Using Oropharyngeal Velum Closure and Exhalation-Driven Gas Flow
US Drug Patent 6,715,485 covers a nasal delivery device that couples (i) closure of the oropharyngeal velum during exhalation to redirect airflow, with (ii) a nosepiece and sealing member that deliver a gas flow entraining a substance into one nostril in a way that drives flow around the posterior margin of the nasal septum and out the other nostril. The core patent strategy is structural and functional: create a controlled, sealed, oropharyngeal-exhalation interface and generate pressurized, directional flow that improves substance transport across the nasal airway.
What does claim 1 of US 6,715,485 require and how broad is the core invention?
Claim 1 elements (device architecture + functional flow geometry)
Claim 1 sets the baseline scope. A device infringes claim 1 if it includes:
- Nasal delivery device delivering to the nasal airway.
- Closure unit that causes closure of the oropharyngeal velum.
- Delivery unit delivering a gas flow entraining a substance to one nostril.
- Driving pressure set so that, in use, the gas flow flows around the posterior margin of the nasal septum and exits via the other nostril.
- Delivery unit includes:
- Nosepiece with an outlet delivering the flow to the one nostril; and
- Sealing member providing a fluid-tight seal between the outlet and the one nostril.
Scope implications
- Structural anchors are explicit: closure unit, nosepiece outlet, sealing member, plus delivery unit producing entraining gas flow.
- Functional geometry is explicit: “around the posterior margin of the nasal septum” is a performance/flow-path limitation that can narrow infringement to devices that achieve that routing under physiological use.
- Bicomponent airflow concept is explicit: closure of the oropharyngeal velum enables the oral/exhalation interaction to become the driving source for nasal routing. Devices that generate nasal flow without velum closure risk non-infringement on that element.
Claim 1 infringement risk profile
- High risk of design-around sits in two places:
- Oropharyngeal velum closure: if a competing design uses a different mechanism (e.g., purely external nasal seals with a compressor, or a different anatomical closure) it may avoid the closure element.
- Posterior nasal septum bypass flow: devices that deliver primarily into the anterior nasal cavity without achieving the claimed posterior-margin routing may attempt to argue lack of the functional flow-path.
How do claims 2–3 (mouthpiece + flow resistor + positive pressure differential) change the claim scope?
Claim 2 adds an exhalation interface and a mouth flow resistor
Claim 2 requires:
- Closure unit includes a mouthpiece through which the subject exhales.
- A flow resistor connected to the mouthpiece provides flow resistance to the exhaled air.
This ties the velum closure to a controlled exhalation flow environment.
Claim 3 quantifies pressure differential
Claim 3 requires the flow resistor be configured to maintain a positive pressure differential of at least about 5 cm H₂O upstream vs. downstream on exhalation.
Scope and enforceability effect
- Quantification strengthens enforceability and narrows the claim: a competitor could potentially argue their flow resistance does not maintain the specified pressure differential in use.
- Claim 3 is still “configured to maintain,” so actual measured performance is relevant. In disputes, claim construction and device test protocols matter.
What do claims 4–8 (delivery channel, gas supply separate to exhalation, control unit) cover?
Claims 4–6: delivery channel and gas supply entraining a substance
- Claim 4: delivery channel receives the substance to be delivered to the one nostril.
- Claim 5: supply unit supplies a gas flow entraining the substance to the nosepiece.
- Claim 6: supply unit delivers gas flow separate to an exhalation flow.
This is a key architecture choice. Claim 1 can be read broadly on gas flow generation, but claims 5–6 clarify a system where exhalation is used for closure/valve-like control and pressure dynamics, while the entraining gas can be supplied separately.
Claims 7–8: actuation/control tied to exhalation
- Claim 7: actuation mechanism actuates supply unit in response to exhalation.
- Claim 8: control unit controls supply unit to control flow rate.
Practical scope
- The invention anticipates a device where exhalation is a trigger, while an engineered gas stream entrains the substance. A system that always runs gas supply independent of exhalation could attempt to design around “in response to exhalation,” but it might still meet other claim elements if trigger language appears in dependent claims only.
What do claims 9–13 add (movable member + impeller entraining airflow + rotatable flow resistor)?
Claim 9: impeller operably coupled to a movable member
Claim 9 introduces:
- Closure unit: mouthpiece + movable member moving on exhalation.
- Delivery unit: delivery channel receives substance.
- Adds an impeller coupled to the movable member such that it moves with the movable member and develops gas flow through the delivery channel to entrain the substance.
This expands the mechanism from a supply unit to a mechanically driven airflow generation scheme.
Claim 10–12: movable member acts as flow resistor and sets pressure
- Claim 10: movable member acts as a flow resistor providing resistance to exhaled air.
- Claim 11: movable member maintains positive pressure upstream of at least about 10 cm H₂O.
- Claim 12: movable member is rotatable.
Scope effect
- The movable member + impeller coupling is a strong structural/functional limitation.
- The 10 cm H₂O threshold tightens performance.
- Rotatable member language narrows embodiments: devices using a linear or membrane motion mechanism can argue non-infringement of dependent claims 12, though independent claim 1 may still be asserted depending on other elements.
Claim 13
- Adds dispensing unit for a dose into the delivery channel.
What do claims 14–18 (mouthpiece-to-nosepiece channel + indicators) cover?
Claim 14: channel connecting mouthpiece to nosepiece for exhalation delivery
Claim 14 requires:
- Delivery unit includes mouthpiece and a channel connecting mouthpiece to nosepiece.
- Channel receives substance such that exhalation through mouthpiece delivers substance through nosepiece.
This is an alternate embodiment: it is closer to an “exhalation transports substance” scheme than a separated supply-unit entrainment scheme.
Claims 15–17: second nostril outlet unit + adjustable flow resistor + indicator
Claim 15 adds:
- Outlet unit with a nosepiece fitting the other nostril.
- A flow resistor for resistance to gas exiting the other nostril to maintain positive dynamic pressure upstream of that resistor.
Claim 16: flow resistor is adjustable.
Claim 17: indicator provides a visual/audible signal indicative of achieving predetermined flow rate or pressure upstream thereof.
Claims 18–19: exhalation indicator at the mouthpiece
Claim 18: indicator provides visual/audible signal on exhalation.
Claim 19: indicator comprises a display member moved into view on exhalation.
Scope effect
- Indicator language is dependent, but it matters in claim selection. If a competitor omits indicators, dependent claims may not be met; core claim 1 may still be in play if all core elements are present.
What do claims 20–21 and 39–40 (combination with medicaments/cleansing/irrigating agents) add?
Combination claims
- Claim 20: combination of delivery device of claim 1 and substance to be delivered.
- Claim 21: substance is one or more of:
- medicament,
- cleansing agent for cleansing the nasal airway,
- irrigating agent for irrigating the nasal airway.
Claims 39–40 are parallel but tied to claim 22’s device scope.
Scope implications
- Combination claims can expand the infringement surface to “method or composition partners” by tying the device to categories of substances.
- If a competitor uses a specific class of drug, these combination claims may be invoked if the substance fits one of the enumerated categories.
- The claim text is category-based, not limited to specific active ingredients or formulations, so it is broad on substance type.
How does claim 22 differ from claim 1? Is it a narrowing or a re-state?
Claim 22 is a re-statement of the device concept with similar elements:
- closure unit causing closure of the oropharyngeal velum;
- delivery unit delivering a substance to one nostril;
- delivery unit includes nosepiece with outlet and sealing member providing fluid-tight seal between outlet and the one nostril.
Claim 22 does not explicitly restate the “posterior margin of the nasal septum and out the other nostril” functional routing in the excerpted claim text, but it mirrors the same overall architecture. Dependent claims 23–38 then reintroduce mouthpiece flow resistor, pressure thresholds, delivery channel, supply unit separate from exhalation, control/actuation, movable member with impeller, adjustable outlet resistor, indicators, and so on.
What this means for claim mapping
- In infringement analysis, claim 1 is likely the strongest independent hook because it contains the explicit posterior nasal septum bypass/outflow limitation.
- Claim 22 can serve as a fallback if the posterior-margin routing becomes a battleground issue, since it reads as a broader structural statement around velum closure plus sealed nosepiece outlet.
What is the legal “center of gravity” of the patent estate for this subject matter?
US 6,715,485’s claim set centers on:
- Anatomical closure: oropharyngeal velum closure during exhalation.
- Sealed nasal interface: fluid-tight seal at the nosepiece outlet.
- Directional pressure-driven nasal flow: driving pressure that produces posterior nasal septum bypass (in claim 1) and dynamic pressure maintenance at the exit nostril (claim 15).
- Controlled actuation: gas supply actuated in response to exhalation, with flow-rate control (claims 7–8).
- Alternative airflow generation: mechanically coupled movable member and impeller (claims 9–12).
- User feedback: indicators tied to exhalation and achieved flow/pressure (claims 17–19).
This structure means the invention is not limited to any one drug, dose form, or formulation. It is primarily a device mechanism patent with combination claims.
Which design-arounds are most consistent with the claim limitations?
Based on the claim language:
-
Avoid velum closure
A competing device that does not cause closure of the oropharyngeal velum during use is the cleanest avoidance path against both claim 1 and claim 22.
-
Eliminate or change the fluid-tight sealing member at the outlet
If the nosepiece interface is not fluid-tight between the outlet and the nostril, the sealing-member element is not met.
-
Change pressure/dynamic routing strategy
For claim 1, a device that does not achieve flow around the posterior margin of the nasal septum and out the other nostril targets the key functional limitation. For claim 3, competitors can test whether they meet “at least about 5 cm H₂O” upstream/downstream differential. For claim 11, test against “at least about 10 cm H₂O.”
-
Replace mechanically driven impeller architecture
A device that uses a purely electronic compressor and a fixed airway restrictor avoids the movable member + impeller linkage in dependent claims 9–12 (without necessarily escaping claim 1/22 if those core elements are still present).
-
Remove adjustable outlet resistor and/or indicators
Omitting adjustable flow resistor at the exit nostril and omitting achieved-flow/pressure indicators can avoid dependent claims 15–17 and 18–19.
How strong is the “pressure threshold” strategy (5 cm H₂O and 10 cm H₂O)?
The dependent claims convert qualitative “resistance” and “positive pressure” into quantitative minimums:
- Claim 3: ≥ about 5 cm H₂O pressure differential upstream vs downstream on exhalation.
- Claim 11: movable-member scheme provides at least about 10 cm H₂O upstream on exhalation.
In enforcement terms:
- These thresholds provide clear target values for validity and infringement analysis.
- They also create testable design-around points: if the competitor can reliably demonstrate their device does not reach those pressure differentials in use, they can avoid dependent claim scope.
Which jurisdictions matter for exclusivity and how does this interact with FDA drug regulation?
This patent is a device-delivery mechanism patent with combination claims to medicaments/cleansing/irrigating agents. For FDA drug regulatory exclusivity and Orange Book status, enforceability typically arises only when the patented invention is listed in the FDA publication for a specific drug product and/or when a formulation or biologic partner is tied to the patented device.
From a business standpoint:
- Patent enforcement pathway is likely against manufacturers of the device and/or the marketed drug-device combination if the combination claims are asserted.
- Paragraph IV and Hatch-Waxman exclusivity mechanisms are relevant only if the patent is listed in the Orange Book for a covered drug product and is asserted in ANDA contexts. If not listed, device enforcement can still proceed via patent law, but Hatch-Waxman timing triggers may not apply.
Patent landscape and competitive mapping: what other players typically compete in this niche?
Without a complete dataset of other specific US patents, applicant/assignee continuations, and device product families tied to US 6,715,485 in public records, a reliable named-landscape cannot be produced from the claim text alone. The actionable landscape for this patent category typically includes:
- nasal irrigation delivery systems using pressurized flow and seals,
- exhalation-actuated nasal delivery devices,
- drug-device combination products where airflow control and sealing mechanisms are patented.
A correct competitor map requires actual bibliographic and prosecution data for US 6,715,485 and citations or family members.
Key Takeaways
- US 6,715,485 is a nasal delivery device patent defined by velum closure, a sealed nosepiece outlet, and controlled gas-flow entrainment that routes flow through the nasal cavity in a way that includes posterior nasal septum bypass (explicit in claim 1).
- The tightest constraints for infringement are the oropharyngeal velum closure, fluid-tight sealing member, and (for claim 1) the posterior margin of the nasal septum bypass and outflow through the other nostril.
- Dependent claims add enforceable quantitative thresholds (≥ about 5 cm H₂O and ≥ about 10 cm H₂O) and specific mechanisms (mouthpiece flow resistor; movable member with impeller; rotatable member).
- Combination claims broadly cover the device when paired with a medicament or nasal cleansing/irrigating agent, without restricting to an active ingredient.
FAQs
-
Does US 6,715,485 require a specific substance formulation or active ingredient?
No. The device claims are generic to “a substance,” and combination claims cover medicaments and nasal cleansing/irrigating agents as categories.
-
What is the most litigable limitation in claim 1: the seal, velum closure, or the posterior septum bypass?
The posterior septum bypass is explicitly functional and may become central in factual infringement disputes, but the seal and velum closure are explicit structural/anatomical elements that are also straightforward to contest.
-
How can a competitor design around the pressure-differential limitations?
By engineering the exhalation flow resistance and measuring upstream/downstream pressure differential to ensure it does not meet the claimed minimums in the relevant “in use” configuration.
-
Are the indicator features essential for all infringement?
No. Indicators are in dependent claims; a competitor could omit indicators and still potentially infringe the independent claims if other elements are met.
-
Can the patent be asserted if a competitor uses a different airflow generation mechanism than an impeller coupled to a movable member?
Dependent claims 9–12 may be avoided, but independent claim scope still depends on whether the core requirements (velum closure, sealed nosepiece outlet, entraining gas flow, and claimed routing in claim 1) are met.
References (APA)
- United States Patent No. 6,715,485.
